*The recommended starting dose is 2.5 mg.2

Important Safety Information

  • ZOMIG is contraindicated in patients with
    • History of coronary artery disease (CAD)
      or coronary artery vasospasm
    • Symptomatic Wolff-Parkinson-White syndrome
      or other cardiac accessory conduction pathway
    • History of stroke, transient ischemic attack,
      or hemiplegic or basilar migraine
    • Peripheral vascular disease
    • Ischemic bowel disease
    • Uncontrolled hypertension
    • Recent (within 24 hours) use of another
      5-HT1 agonist (eg, another triptan), or an
      ergotamine-containing medication
    • Monoamine oxidase (MAO)-A inhibitor
      used in past 2 weeks
    • Known hypersensitivity to ZOMIG, ZOMIG-ZMT,
      or ZOMIG Nasal Spray. Anaphylaxis,
      anaphylactoid, and hypersensitivity reactions
      including angioedema have occurred in patients
      receiving zolmitriptan
  • Myocardial ischemia, myocardial infarction and
    Prinzmetal’s Angina: Perform cardiac evaluation
    in patients with multiple risk factors and, if
    satisfactory, administer first dose of ZOMIG in
    a medically supervised setting
  • Arrhythmias: Discontinue ZOMIG if these occur
  • Sensations of tightness, pain and pressure in the
    chest, throat, neck, and jaw commonly occur after
    treatment with 5-HT1 agonists like ZOMIG and are
    usually non-cardiac in origin: Perform a cardiac
    evaluation if these patients are at cardiac risk
  • Cerebrovascular events, some fatal; non-coronary
    Gastrointestinal Ischemic Reactions and
    Peripheral Vasospastic Reactions; and increases
    in blood pressure (which have been very rarely
    associated with serious clinical events) have been
    reported with ZOMIG. Discontinue use of ZOMIG
    if any of these events occur
  • Overuse of acute migraine drugs may lead to
    exacerbation headache (medication overuse
    headache). Detoxification of patients, including
    withdrawal of the overused drugs, and treatment of
    withdrawal symptoms may be necessary
  • Serotonin syndrome may occur with triptans,
    including ZOMIG, particularly during
    co-administration with selective serotonin reuptake
    inhibitors (SSRIs), serotonin norepinephrine
    reuptake inhibitors (SNRIs), tricyclic
    antidepressants (TCAs), and MAO inhibitors.
    Discontinue ZOMIG if serotonin syndrome is
  • The most common adverse reactions in adults
    (≥5% and > placebo; in any dosage strength) in
    clinical trials for ZOMIG Nasal Spray were: unusual
    taste, paresthesia, hyperesthesia, and dizziness
  • The most common adverse reaction in pediatrics
    (age 12 to 17 years; ≥5% and > placebo; in either
    the 2.5 or 5 mg ZOMIG dose groups) in clinical
    trials for ZOMIG Nasal Spray was unusual taste


ZOMIG Nasal Spray is a serotonin (5-HT)1B/1D
receptor agonist (triptan) indicated for the acute
treatment of migraine with or without aura in adults
and pediatric patients 12 years and older.

Limitations of Use:

Use ZOMIG only after a clear diagnosis of migraine
has been established. If a patient has no response
to ZOMIG treatment for the first migraine attack,
reconsider the diagnosis of migraine before ZOMIG
is administered to treat any subsequent attacks.
ZOMIG is not indicated for the prevention of
migraine attacks. Safety and effectiveness of
ZOMIG have not been established for cluster
headache. ZOMIG Nasal Spray is not
recommended in patients with moderate to severe
hepatic impairment.

Click here to see the full Prescribing Information
for ZOMIG Nasal Spray.

Click here to see the full Prescribing Information
for ZOMIG Tablets and ZOMIG-ZMT Orally
Disintegrating Tablets.

You are encouraged to report negative side
effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
contact Impax Laboratories, Inc. at

References: 1. Data on file, REF-MED-ZNS-US-0002,
Impax Laboratories, Inc. 2. ZOMIG Nasal Spray
[package insert]. Hayward, CA: Impax Specialty
Pharma, a division of Impax Laboratories, Inc.; 2016.

ZOMIG is a registered trademark of the AstraZeneca
group of companies.

© 2017 Impax Specialty Pharma, a division of Impax
Laboratories, Inc. All rights reserved.
PP-ADW-ZNS-US-0031 05/2017